Company Filing History:
Years Active: 2017-2025
Title: Usha R Pendurthi: Innovator in Hemophilia and Cancer Research
Introduction
Usha R Pendurthi is a notable inventor based in Tyler, TX (US), recognized for her contributions to medical research, particularly in the fields of hemophilia and cancer treatment. With a total of 2 patents, her work focuses on innovative therapeutic approaches that address significant health challenges.
Latest Patents
One of her latest patents is titled "Treatment and prevention of hemophilic arthropathy with an antibody against endothelial cell protein C receptor (EPCR)." This invention involves the use of a blocking antibody, specifically a monoclonal antibody (mAb), that targets the human endothelial cell protein C receptor (EPCR). The application of this antibody aims to reduce joint swelling, macrophage infiltration, iron deposition, and blood vessel formation, ultimately treating arthropathy in hemophilic subjects.
Another significant patent is "Suppression of malignant mesothelioma by overexpression or stimulation of endothelial protein C receptors (EPCR)." This research explores the roles of tissue factor (TF), EPCR, and protease-activated receptor-1 (PAR1) in the tumor growth of malignant pleural mesothelioma (MPM). The findings indicate that manipulating the expression of these receptors can influence tumorigenicity, providing insights into potential therapeutic strategies for MPM.
Career Highlights
Usha R Pendurthi is affiliated with the University of Texas System, where she conducts her research and develops her innovative solutions. Her work has garnered attention for its potential impact on treating complex medical conditions.
Collaborations
Usha collaborates with esteemed colleagues, including Vijaya M Lella and Jhansi L Magisetty, contributing to a dynamic research environment that fosters innovation and discovery.
Conclusion
Usha R Pendurthi's contributions to medical research through her patents highlight her commitment to advancing treatment options for hemophilia and cancer. Her innovative approaches continue to pave the way for future developments in these critical areas of healthcare.